CB676475: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5329006 |
| CHEMBL ID | 150315 |
| CHEBI ID | 92732 |
| SCHEMBL ID | 3012896 |
| MeSH ID | M0496095 |
| Synonym |
|---|
| chembl150315 , |
| n-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine |
| bdbm4621 |
| anilinoquinazoline deriv. 4 |
| 690206-97-4 |
| BRD-K41337261-001-01-4 |
| HSCI1_000042 |
| NCGC00167747-01 |
| cb-676475 |
| HY-13785 |
| zm 306416 , |
| CS-1349 |
| zm306416 |
| zm-306416 |
| S2897 |
| gtpl8245 |
| zm-306416(cb 676475) |
| SCHEMBL3012896 |
| c16h13clfn3o2 |
| DTXSID90416176 |
| AC-32069 |
| cb676475 |
| cb 676475 |
| AKOS025404926 |
| mfcd02683969 |
| CHEBI:92732 |
| HMS3651N06 |
| n-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine |
| SW219943-1 |
| FT-0706412 |
| BCP06445 |
| 4-[(4'-chloro-2'-fluoro)phenylamino]-6,7-dimethoxyquinazoline |
| Q27089298 |
| AMY16243 |
| BRD-K41337261-003-01-0 |
| 4-quinazolinamine, n-(4-chloro-2-fluorophenyl)-6,7-dimethoxy- |
| SB16593 |
| CCG-267845 |
| AS-57308 |
| 4-quinazolinamine,n-(4-chloro-2-fluorophenyl)-6,7-dimethoxy- |
| A866937 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Oral administration of selected compounds to mice produced total plasma levels 6 h after dosing of between 3 and 49 microM." | ( Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. Curwen, JO; Dukes, M; Hennequin, LF; Johnstone, C; Kendrew, J; Lambert-van der Brempt, C; Lohmann, JJ; Ogilvie, DJ; Plé, PA; Stokes, ES; Thomas, AP; Wedge, SR, 1999) | 0.3 |
| " Follow-up dose-response studies revealed that 12 of the 13 known EGFR inhibitors in the library were confirmed as hits." | ( A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. Antczak, C; Bhinder, B; Calder, PA; Djaballah, H; Mahida, JP, 2012) | 0.38 |
| Class | Description |
|---|---|
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 4.0250 | 0.0002 | 0.9420 | 10.0000 | AID1795652; AID72245 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 9.5077 | 0.0001 | 0.2914 | 7.0000 | AID1795652; AID216627; AID258541; AID258542; AID408111; AID476558; AID481531; AID481816; AID636125; AID650454; AID734140 |
| Ephrin type-B receptor 2 | Homo sapiens (human) | IC50 (µMol) | 8.5000 | 0.0025 | 1.5875 | 8.5000 | AID240825 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0001 | 0.2264 | 4.9000 | AID258541 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 1.9500 | 0.0000 | 0.4830 | 8.8000 | AID1795652; AID216644; AID258540; AID258541 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Ephrin type-B receptor 2 | Homo sapiens (human) | Kd | 6.2000 | 0.0004 | 3.1536 | 53.1980 | AID238118 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1795652 | VEGF-R Kinase Inhibition Assay from Article 10.1021/jm990345w: \\Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.\\ | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID216644 | Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID258540 | Inhibitory activity against VEGFR2 kinase | 2006 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1 | Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. |
| AID216627 | In vitro vascular endothelial growth factor receptor 1 inhibitory activity at 2 uM of ATP. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID238118 | Equilibrium binding constant for EPH receptor B2 | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9 | Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. |
| AID241428 | Inhibition of EphB2 receptor tyrosine kinase in ELISA assay | 2004 | Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21 | Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA. |
| AID734140 | Inhibition of VEGF-induced VEGFR1 phosphorylation in human A498 cells overexpressing Flt-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis | 2013 | Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5 | N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastati |
| AID240825 | Inhibition of EPH receptor B2 using ELISA | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9 | Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. |
| AID650454 | Inhibition of VEGF-induced VEGFR1 autophosphorylation in human A498 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. |
| AID258541 | Inhibitory activity against VEGF-stimulated proliferation in HUVEC | 2006 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1 | Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. |
| AID481531 | Inhibition of VEGFR1 | 2010 | Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10 | The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. |
| AID233586 | Ratio of IC50 of FGFR-1 (FTK) to VEGFR-2 (KDR). | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID636125 | Inhibition of VEGFR1 tyrosine kinase activity in VEGF-stimulated human A498 cells after 60 mins by ELISA | 2012 | Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2 | N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. |
| AID193938 | Percent inhibition of VEGF-mediated estradiol benzoate-induced rat uterus weight gain at 100 mg/kg oral dose | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID476558 | Inhibition of VEGFR1 in human A498 cells by phosphotyrosine cell-based ELISA | 2010 | Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4 | Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. |
| AID481816 | Inhibition of VEGFR1 phosphorylation in human A498 cells after 10 mins by FLISA | 2010 | Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10 | Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. |
| AID72245 | FGFR-1 (FTK) inhibitory activity at 2 uM of ATP in vitro. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID233585 | Ratio of IC50 of FGFR-1 (FTK) to VEGFR-1 (Flt). | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID408111 | Inhibition of VEGFR1 expressed in human tumor cells | 2008 | Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10 | Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. |
| AID258542 | Inhibitory activity against flt kinase | 2006 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1 | Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. |
| AID238116 | Binding constant for EphB2 tyrosine kinase | 2004 | Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21 | Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA. |
| AID1345548 | Human fms related tyrosine kinase 1 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2012 | Journal of biomolecular screening, Aug, Volume: 17, Issue:7 | A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. |
| AID1345548 | Human fms related tyrosine kinase 1 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID1345506 | Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. |
| AID1345502 | Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family) | 2012 | Journal of biomolecular screening, Aug, Volume: 17, Issue:7 | A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||